# US 2019/0375746 A1 · Benzoquinoline inhibitors of vesicular monoamine transporter 2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375746 A1
- Document ID: US20190375746A1
- Status: Published application
- Kind: A1
- Application number: 16/210,077
- Filed: 2018-12-05
- Published: 2019-12-12
- Earliest claimed: 2008-09-18
- Assignees: Auspex Pharmaceuticals, Inc.
- Applicants: Auspex Pharmaceuticals, Inc.
- Inventors: Thomas G. Gant; Manouchehr Shahbaz
- Web page: https://patentgrep.com/patent/US20190375746A1

## CPC

- C07D 455/06: containing benzo [a] quinolizine ring systems
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 59/002: {Heterocyclic compounds}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

## Claims

### Claim 1

A compound that is
wherein each position indicated as D has deuterium enrichment of at least 50%.

### Claim 2 (depends on 1)

The compound of claim 1, wherein each position indicated as D has deuterium enrichment of no less than about 90%.

### Claim 3 (depends on 1)

The compound of claim 1, wherein each position indicated as D has deuterium enrichment of no less than about 98%.

### Claim 4 (depends on 1)

The compound of claim 1 that is:

### Claim 5 (depends on 1)

The compound of claim 1 that is:

### Claim 6 (depends on 4)

A pharmaceutical composition comprising a compound as recited in claim 4 together with a pharmaceutically acceptable carrier.

### Claim 7 (depends on 5)

A pharmaceutical composition comprising a compound as recited in claim 5 together with a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A method of treating a VMAT2-mediated disorder in a subject comprising administering to the subject a compound of claim 1.

### Claim 9 (depends on 8)

The method of claim 8, wherein the VMAT2-mediated disorder is a chronic hyperkinetic movement disorder.

### Claim 10 (depends on 9)

The method of claim 9, wherein the chronic hyperkinetic movement disorder is Huntington's disease.

### Claim 11 (depends on 9)

The method of claim 9, wherein the chronic hyperkinetic movement disorder is chorea related to Huntington's disease.

### Claim 12 (depends on 9)

The method of claim 9, wherein the chronic hyperkinetic movement disorder is Tardive dyskinesia.

### Claim 13 (depends on 9)

The method of claim 9, wherein the chronic hyperkinetic movement disorder is Tourette's syndrome.

### Claim 14 (depends on 8)

The method of claim 8, wherein the subject is human.

### Claim 15 (depends on 8)

The method of claim 8, further resulting in at least one effect selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 16 (depends on 8)

The method of claim 8, wherein the treatment effects a decreased metabolism of the compound per dosage unit thereof by at least one polymorphically-expressed cytochrome P450 isoform selected from the group consisting of CYP2C8, CYP2C9, CYP2C19, and CYP2D6 in the subject, as compared to the corresponding non-isotopically enriched compound.

### Claim 17 (depends on 8)

The method of claim 8, resulting in decreased inhibition of at least one cytochrome P450 or monoamine oxidase isoform selected from the group consisting of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4X1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, CYP51, MAOA, and MAOB in the subject per dosage unity, as compared to the non-isotopically enriched compound.

### Claim 18 (depends on 8)

The method of claim 8, resulting in a reduced deleterious change in a diagnostic hepatobiliary function endpoint selected from the group consisting of alanine aminotransferase (“ALT”), serum glutamic-pyruvic transaminase (“SGPT”), aspartate aminotransferase (“AST” or “SGOT”), ALT/AST ratios, serum aldolase, alkaline phosphatase (“ALP”), ammonia levels, bilirubin, gamma-glutamyl transpeptidase (“GGTP,” “γ-GTP,” or “GGT”), leucine aminopeptidase (“LAP”), liver biopsy, liver ultrasonography, liver nuclear scan, 5′-nucleotidase, and blood protein, as compared to the corresponding non-isotopically enriched compound.

### Claim 19 (depends on 8)

The method of claim 8, wherein the compound is administered with an additional therapeutic agent.

### Claim 20 (depends on 19)

The method of claim 19, wherein said additional therapeutic agent olanzapine, pimozide, a benzodiazepine, or an antipsychotic.
